Real-time · AI · Cross-signal

Discover the power of real-time signals plus AI

Every contract, funding round, exec hire, and M&A move on CROSSJECT — with verified, ICP-scored contact reveals (email + mobile) on demand.

Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.

See plans Book a 15-min walkthrough

▶

Watch the 2-minute tour · with sound

Crossject launches reserved capital increase and warrants issuance for an aggregate amount of at least €7m

Dec 10, 2024•over 1 year ago

Contract Type

partnership

DijonBiotechnologyPharmaceutical

Description

Crossject has engaged Maxim Group LLC as lead placement agent and Invest Securities as co-placement agent for a private placement comprising an issue of new ordinary shares and warrants for a total gross amount of at least EUR 7 million. The proceeds are expected to result in a total cumulative gross amount of at least EUR 7 million in immediate new funding for the Company.

Company Information

Company

CROSSJECT

Location

Dijon, Bourgogne – Franche-Comté, France

About

Crossject SA is an emerging specialty pharma company based in France and the U.S. It is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it was awarded a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company’s award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing. The Company’s other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks.

Predictive Intelligence

Strategic

ML-powered predictions for CROSSJECT's next move

Learn about Strategic plan

Related People

Suggested for you

Agreement Insights

Based on industry data

Strategic partnership established

Partnership agreements typically involve technology integration and joint go-to-market strategies

Contract momentum indicator

Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months